Industry Trends

As Congress once again takes up legislation to reduce drug prices, one of the most important yet overlooked areas for reform is rebate walls. Rebate walls, also known as rebate traps, block competition in parts of the U.S. prescription drug market, especially immunology, which is home to some of the costliest drugs. They can favor older, more expensive and even less effective drugs over newer, more effective, and often cheaper alternatives. Thanks to rebate walls, patients are routinely forced to “fail first”...

Patent trolls have been a plague on innovators for too long. Patent trolls are entities that obtain patents (sometimes obscure patents) for the sole purpose of threatening or filing lawsuits in court and then using the prospect of costly litigation to extort unwarranted payouts from an innovative company. The risks and costs created by these entities are a clear and present danger to entrepreneurship and innovation. A goal of public policy should be to make it more costly for frivolous patent...

BY ROBERT POPOVIAN & WAYNE WINEGARDEN President Joe Biden should take advantage of a bipartisan opportunity to meaningfully reduce patients’ out-of-pocket spending on biopharmaceuticals. Seizing this opportunity requires the president to recognize that the drug cost problem exists because the current system inappropriately shifts too much of its expenditures to patients. Consider that hospitals’ total expenditure in 2019 was $1.2 trillion, or three times the total of the spend on pharmaceuticals. However, patients’ out-of-pocket spending on drugs in 2019 was $54 billion, or 50 percent higher than...

By Wayne Winegarden and Robert Popovian The Department of Health and Human Services (HHS) finalized a regulation on November 20, 2020 that removed the safe harbor protections for rebates on prescription drugs paid to pharmacy benefit managers (PBMs) and Part D plans. This analysis evaluates the expected impact from this regulation on Medicare premiums and patient out-of-pocket (OOP) costs. Based on the data from the California Department of Managed Health Care (DMHC), the loss of manufacturer drug rebates would cause the average insurance...

Pacific Research Institute senior fellow and economist Dr. Wayne Winegarden talks free market energy, California rolling power blackouts, and optimistic solutions to energy policy on The Roth Effect with Carol Roth. Winegarden also discusses his recent studies that challenge green energy, fracking, electric vehicles, and more. [embed]https://mp3.ricochet.com/2020/09/Roth_Effect_66.mp3[/embed]...

By: Kathleen Hefferon, Ph.D., and Henry Miller, M.S., M.D. COVID-19 has turned our world upside down in so many ways, and the food supply chain is no exception. Whether consumers prefer fast or slow food, meat-based or vegan, local or imported, organic or conventional, supermarkets or farmers’ markets, every aspect of our food supply chain, from farm to fork, has been affected by this scourge. The recent, rampant outbreaks of COVID-19 among meat-processing workers – over the past month or so, the...

Listen to Dr. Henry Miller, PRI senior fellow in health studies, discuss the move by the WHO to pause hydroxychloroquine trials for Coronavirus treatment on the nationally-syndicated Lars Larson Show. TheLarsLarsonShow · Dr. Henry Miller - WHO pauses hydroxychloroquine trials for Coronavirus treatment...

Dr. Henry Miller joined the nationally-syndicated Lars Larson Show to talk about the latest updates with the coronavirus, including the rapid spread of the number of cases in the United States and across the globe and how different states have reacted to the threat of COVID-19. Miller also talks about the questionable coverage by both sides of the media on the coronavirus. ...

The excellent and informative articles “Want a Test? Depends Where You Live” (The Coronavirus Pandemic, March 12) and “Don’t Jump to Conclusions” (Heard on the Street, March 11) about testing for the new coronavirus didn’t cover some important nuances. The test kits in use in the U.S. described in the articles detect viral genetic material—RNA, in the case of coronaviruses—which can be infectious material or noninfectious fragments. Once the patient has recovered and the RNA has been cleared, the tests will...

The New York Post last week published an article with the ominous headline, “Pharmacists quietly panicking over looming respiratory drug shortage.” The gist was that in addition to the rush on personal protection products such as face masks, hand sanitizers, disinfectants, and rubber gloves, the supply chains for various important prescription drugs, especially generics with components made in China, are fraying. This should come as no surprise. As the number of cases of infection with the novel coronavirus (formally SARS-CoV-2, with the illness it...

Title: As U.S. Sees COVID-19 Infections Spike, Some Worry About 'Grave Errors' By Adam Smith In the beginning, the few reports of a newly discovered virus seemed inconsequential and distant. The coronavirus was causing pneumonia in scores of people, but those patients were in a faraway province of China, Hubei, that most outside that nation had never heard of. “There is no evidence that the new virus is readily spread by humans, which would make it particularly dangerous, and it has not been...

Fractions are taught in elementary school, but adults sometimes still manage to misunderstand how they work in everyday life. I was reminded of that after President Trump’s Saturday press conference, which focused on the federal government’s response to the Wuhan coronavirus (formally SARS-CoV-2, with the illness it causes designated COVID-19). Let me explain. Dr. Anthony Fauci, the articulate, veteran director of the National Institute of Allergy and Infectious Diseases, described at the presser how the efforts to prevent the spread—or “contain”...

CDC warns on coronavirus in US: Should you start to worry? By Madeline Farber, Fox News Federal health officials this week warned that community spread of the novel coronavirus in the U.S. is seemingly inevitable, with one Centers for Disease Control and Prevention (CDC) official saying it’s no longer “a question of if, but when, and how many people in this country will have severe illness.” In the same vein, officials have maintained that the immediate threat to the public remains low. So how worried should you be?...

Dr. Henry Miller, PRI’s senior fellow for the Center for Medical Economics and Innovation, joins the John Batchelor Show to offer analysis on the search for a vaccine for the coronavirus. Dr. Miller says the United States has a steep learning curve ahead for dealing with the coronavirus pandemic and talks about the latest developments from the World Health Organization.  ...

PRI's Henry Miller, M.S., M.D., joins the nationally-syndicated Lars Larson Show to discuss the latest developments in the spread of the coronavirus. Larson and Dr. Miller look at the rise of coronavirus cases in South Korea and Italy, and what the United States is doing to prepare for the impact of the pandemic. Miller's segment begins at the 47:00 minute mark. ...

The World Health Organization, a part of the United Nations, has proposed an official name, COVID-19, for the illness caused by the Wuhan coronavirus, after the city in China where it emerged. (The new designation stands for coronavirus disease 2019, as the illness was first detected toward the end of last year.) The director-general of WHO, Tedros Adhanom Ghebreyesus, noted that the name was chosen “to avoid stigma”—or as the woke might say, microaggressions—thus, the new name makes no reference to...